Cargando…

Nanoparticles for transcutaneous vaccination

The living epidermis and dermis are rich in antigen presenting cells (APCs). Their activation can elicit a strong humoral and cellular immune response as well as mucosal immunity. Therefore, the skin is a very attractive site for vaccination, and an intradermal application of antigen may be much mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Steffi, Lehr, Claus‐Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815776/
https://www.ncbi.nlm.nih.gov/pubmed/21854553
http://dx.doi.org/10.1111/j.1751-7915.2011.00284.x
_version_ 1782289439171543040
author Hansen, Steffi
Lehr, Claus‐Michael
author_facet Hansen, Steffi
Lehr, Claus‐Michael
author_sort Hansen, Steffi
collection PubMed
description The living epidermis and dermis are rich in antigen presenting cells (APCs). Their activation can elicit a strong humoral and cellular immune response as well as mucosal immunity. Therefore, the skin is a very attractive site for vaccination, and an intradermal application of antigen may be much more effective than a subcutaneous or intramuscular injection. However, the stratum corneum (SC) is a most effective barrier against the invasion of topically applied vaccines. Products which have reached the stage of clinical testing, avoid this problem by injecting the nano‐vaccine intradermally or by employing a barrier disrupting method and applying the vaccine to a relatively large skin area. Needle‐free vaccination is desirable from a number of aspects: ease of application, improved patient acceptance and less risk of infection among them. Nanocarriers can be designed in a way that they can overcome the SC. Also incorporation into nanocarriers protects instable antigen from degradation, improves uptake and processing by APCs, and facilitates endosomal escape and nuclear delivery of DNA vaccines. In addition, sustained release systems may build a depot in the tissue gradually releasing antigen which may avoid booster doses. Therefore, nanoformulations of vaccines for transcutaneous immunization are currently a very dynamic field of research. Among the huge variety of nanocarrier systems that are investigated hopes lie on ultra‐flexible liposomes, superfine rigid nanoparticles and nanocarriers, which are taken up by hair follicles. The potential and pitfalls associated with these three classes of carriers will be discussed.
format Online
Article
Text
id pubmed-3815776
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-38157762014-02-12 Nanoparticles for transcutaneous vaccination Hansen, Steffi Lehr, Claus‐Michael Microb Biotechnol Minireviews The living epidermis and dermis are rich in antigen presenting cells (APCs). Their activation can elicit a strong humoral and cellular immune response as well as mucosal immunity. Therefore, the skin is a very attractive site for vaccination, and an intradermal application of antigen may be much more effective than a subcutaneous or intramuscular injection. However, the stratum corneum (SC) is a most effective barrier against the invasion of topically applied vaccines. Products which have reached the stage of clinical testing, avoid this problem by injecting the nano‐vaccine intradermally or by employing a barrier disrupting method and applying the vaccine to a relatively large skin area. Needle‐free vaccination is desirable from a number of aspects: ease of application, improved patient acceptance and less risk of infection among them. Nanocarriers can be designed in a way that they can overcome the SC. Also incorporation into nanocarriers protects instable antigen from degradation, improves uptake and processing by APCs, and facilitates endosomal escape and nuclear delivery of DNA vaccines. In addition, sustained release systems may build a depot in the tissue gradually releasing antigen which may avoid booster doses. Therefore, nanoformulations of vaccines for transcutaneous immunization are currently a very dynamic field of research. Among the huge variety of nanocarrier systems that are investigated hopes lie on ultra‐flexible liposomes, superfine rigid nanoparticles and nanocarriers, which are taken up by hair follicles. The potential and pitfalls associated with these three classes of carriers will be discussed. Blackwell Publishing Ltd 2012-03 2012-02-20 /pmc/articles/PMC3815776/ /pubmed/21854553 http://dx.doi.org/10.1111/j.1751-7915.2011.00284.x Text en Copyright © 2011 The Authors. Microbial Biotechnology © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd
spellingShingle Minireviews
Hansen, Steffi
Lehr, Claus‐Michael
Nanoparticles for transcutaneous vaccination
title Nanoparticles for transcutaneous vaccination
title_full Nanoparticles for transcutaneous vaccination
title_fullStr Nanoparticles for transcutaneous vaccination
title_full_unstemmed Nanoparticles for transcutaneous vaccination
title_short Nanoparticles for transcutaneous vaccination
title_sort nanoparticles for transcutaneous vaccination
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815776/
https://www.ncbi.nlm.nih.gov/pubmed/21854553
http://dx.doi.org/10.1111/j.1751-7915.2011.00284.x
work_keys_str_mv AT hansensteffi nanoparticlesfortranscutaneousvaccination
AT lehrclausmichael nanoparticlesfortranscutaneousvaccination